$0.07—Stale · unknown old
9/28/26
WPD Pharmaceuticals (WBIO.CN)
Monday
8:03 PM
ThesisThe recent influx of competitors in the rare disease market is raising concerns about WPD's market share and pricing power.
Revenue Outlook
| Metric | FY2022 | FY2023 |
|---|---|---|
| Revenue | $0.00 | $0.00 |
| Rev. Growth | — | — |
| EPS | $0.03 | $-0.00 |
| EPS Growth | +169% | -102% |
| P/E | 2.1× | — |
What Moves the Stock
- 01Progress in clinical trials for lead drug candidates, particularly in rare diseases
- 02Partnership announcements with larger pharmaceutical firms
- 03Regulatory approvals or setbacks for drug candidates
- 04Changes in market sentiment towards biotech stocks
- 05Product development partnerships - 70%
- 06Research grants - 20%
- 07Licensing agreements - 10%
- 08Increased focus on rare disease treatments
FY2023 Snapshot
- Revenue
- $0.00
- Gross Margin
- 0.0%
- Op. Margin
- 0.0%
- Net Margin
- 0.0%
- Net Income
- $-80.1K
- NI Growth
- -102%
- EPS
- $-0.00
- 1Y Return
- -44.0%
WBIO.CN Chart
My Notes
- "The landscape is becoming increasingly crowded, which could impact our growth trajectory."
- Moat: WPD's expertise in rare diseases provides a competitive edge, but the moat is vulnerable to rapid innovation from larger firms.
- growth - Investors looking for high-risk, high-reward opportunities in the biotech sector.
- Higher interest rates could increase the cost of capital for WPD, making it more challenging to finance R&D projects and potentially leading…
- Watch on earnings: Clinical trial success rates, Partnership revenue growth, R&D expenditure trends.
One Sentence Summary:
WPD Pharmaceuticals: the story is balanced — progress in clinical trials for lead drug candidates, particularly in rare diseases.
Auto-composed from Stock Alarm intelligence, financial statements, and analyst estimates. Not investment advice.
Explore More
52-Week Highs Breakout
Stocks breaking to new annual highs
52-Week Lows Oversold
S&P 500 oversold value screener
Trending Momentum
Relative strength momentum leaders
Earnings Calendar
Upcoming earnings dates & reports
S&P 500 Screener
Filter and sort all 500 stocks
Strategy Focus List
Continuous multi-factor scoring & catalyst forensics
Market Movers
Today's biggest gainers and losers